What is a GLP-1 maintenance dose? It is the lowest dose of the medication that holds the result you and your clinician agreed on, whether that result is measured on the scale, on HbA1c or on the waistband. It is a number found in ninety day cycles, read off a lab panel and a symptom list. It is not a step on a ladder you are required to climb. The question of who decides it is the sharper one, because a maintenance dose is the one number in this industry with a price attached on both sides. A program whose revenue rises when the dose rises will always find a reason for the next step. Here is how the decision should work, what the trial record says about staying at a dose and how our structure removes the conflict from the answer.
- A maintenance dose is the lowest dose that holds the result, found over ninety day cycles.
- STEP-1 showed about 15 percent average weight loss on semaglutide 2.4 mg and SURMOUNT-1 showed up to about 22.5 percent on tirzepatide at the highest dose.
- SURMOUNT-4 showed that stopping the medication reversed the loss, which is why maintenance is a clinical decision rather than an afterthought.
- The titration has no financial vote at GoodLife Health because the fee is a flat $299 a month at any dose.
- The pharmacy bills the medication separately at its own cost, so nobody on our side earns more when the dose climbs.
What the trial record calls a maintenance dose
The registration trials did not use the phrase, but they drew the map for it. In STEP-1, adults with obesity on semaglutide 2.4 mg weekly lost about 15 percent of body weight over 68 weeks and roughly a third lost a fifth or more. In SURMOUNT-1, participants on tirzepatide at the 15 mg dose lost up to about 22.5 percent on average over 72 weeks. Those numbers came from doses held steady after a titration period, which is exactly what a maintenance dose is. The medication reaches its working level and the protocol holds there.
The common maintenance doses in practice follow from those trials. For semaglutide, 2.4 mg weekly is the dose the trials used for weight management. For tirzepatide, the 5, 10 and 15 mg doses are all maintenance doses and the lowest one that works is the correct answer for a given patient. The trials stepped patients up gradually to reach those levels and did not include a dose minimization arm, so the honest read of the literature is that we know the doses work. We do not yet know the minimum dose that works, because finding it was never anyone's business model to fund.
That gap is where clinical judgment lives and it is why the decision belongs to a clinician with a panel and a patient rather than to an algorithm with a titration schedule.
How a maintenance dose is actually found
A maintenance dose is not declared on day one. It is discovered and the discovery runs on the quarterly cycle.
- A baseline before any prescription. The Biomarker Audit is drawn first, covering ApoB, HbA1c, fasting insulin, hs-CRP, lipids, a comprehensive metabolic panel, a CBC and TSH with reflex to free T4. Nobody prescribes into an unseen panel.
- A measured titration. The starting dose is low and the steps are deliberate, each one judged on tolerability as much as on the scale. Nausea, reflux and fatigue are data.
- A ninety day review. At each Biomarker Audit the clinician reads the trend together. Weight and symptoms say what changed. The panel says whether the change is the kind you wanted.
- The hold point. When the result is moving at the rate you agreed on and the side effects are quiet, the dose holds there. That is the maintenance dose.
- A deliberate test of the floor. On the review after the hold, the honest question is whether the dose can come down. A planned reduction and a recheck at the next audit answers it with evidence rather than opinion.
The fifth step is the one most programs skip and it is the only one that makes the maintenance dose real. A dose that is never tested downward was never confirmed as the lowest effective dose. It was only confirmed as the dose the patient happens to be on.
A dose that was never tested downward has never been confirmed as the lowest effective dose. It has only been confirmed as the dose you are on.
Why so many programs never let the dose come down
The reason is structural and it is not a mystery. On most weight loss platforms the monthly price rises at the titration. A patient who starts at a low dose and steps up twice pays two higher prices by month six and the platform books every step as revenue. In that model the next dose increase is the profitable move and holding at the current dose is the unprofitable one. No individual clinician on those platforms has to be corrupt. The schedule simply always points up.
The consequence shows up in the complaints we hear from people who left those programs. A dose that kept climbing after the result had already arrived. A plateau answered automatically with the next step rather than with labs. Side effects dismissed because the titration schedule had a box to tick. None of that is medical judgment. It is a business model wearing a white coat.
The maintenance dose question is therefore an incentive question before it is a clinical one. Before you join any program, ask one thing. Who earns more when my dose goes up? If the answer is the program, the titration you are being offered has a silent financial vote in it.


What the dose does to the bill, written out
Our answer to that question is structural rather than rhetorical. The membership is one flat $299 per month for the clinical relationship and four Biomarker Audits a year. The medication is a separate charge billed by the pharmacy at its own cost. The two never touch.
The commitment at the start is two months, paid as a single $598 charge covering the first two months together, including the intake visit and the first Biomarker Audit. From month three the membership is month to month and you can cancel anytime. There are no tiers, no molecule upcharge and no dose escalation fee on our side. If your clinician steps the dose up twice, the fee is $299. If your clinician steps it down twice, the fee is $299. Over a first year that is $3,588 for the doctor and the labs, plus whatever the pharmacy charges for the medication at its own published price.
We make money when you get healthier, not when your dose gets stronger. That sentence is not a slogan. It is a description of where the revenue sits and it is the reason the titration at our practice has no financial vote in it.
Plateaus, dose reviews and when the dose comes down
A plateau during maintenance is common and it deserves a workup rather than a reflex. At the next audit the clinician reads the panel against the symptom list. A plateau with clean markers and a patient who is training is usually a hold. A plateau with a rising HbA1c, a thyroid drifting the wrong way or a fasting insulin creeping up is a conversation about the system around the medication. Sometimes the answer is a dose change. Often it is protein intake, sleep or a training program that stopped being a stimulus.
The dose comes down deliberately, never abruptly. A planned reduction with a recheck at the following audit is how the floor gets tested. Some patients maintain on a reduced dose. Some hold their result with structured taper and the habits they built and some do better staying on the working dose. All three are legitimate clinical outcomes. What matters is that the decision was made on evidence by a clinician whose income did not depend on the answer.
Who this is not for
Three readers, plainly. If you want the highest dose the market will sell regardless of what your panel says, our clinicians will not lead with that and you will be more comfortable elsewhere. If you want compounded vials, we prescribe branded, FDA-approved medication only, Wegovy, Zepbound, Ozempic, Mounjaro, Wegovy Tablets and Foundayo where appropriate and never compounded. If you want a prescription in the first conversation without labs, the Biomarker Audit comes first and we will not skip it.
Frequently Asked Questions
What is a GLP-1 maintenance dose?
It is the lowest dose of the medication that holds the agreed result over time, found through ninety day cycles of measurement and review. The trial maintenance doses were 2.4 mg weekly for semaglutide and 5 to 15 mg weekly for tirzepatide and the lowest one that works for a given patient is the correct one.
Who should decide my maintenance dose?
The clinician who reads your labs and knows your case, together with you. The trials established that these doses work. They did not establish the minimum dose that works, so that part is clinical judgment built on quarterly panels rather than a fixed schedule.
Will my dose keep going up forever?
It should not. A dose that keeps climbing after the result has arrived is a titration that nobody is testing downward. At our practice the floor is tested deliberately, with a planned reduction and a recheck at the next Biomarker Audit.
Does a higher dose cost more at GoodLife Health?
No. The membership is a flat $299 per month at any dose, with a two month commitment to start paid as a single $598 charge covering the first two months. The medication is billed by the pharmacy at its own cost, separately from the fee. Nobody on our side earns more when the dose climbs.
What happens if I stop the medication?
The evidence says most people regain a substantial share of the lost weight within about a year. In SURMOUNT-4, participants who stopped tirzepatide regained roughly two thirds of the lost weight over twelve months. A structured taper and a maintenance plan reduce that risk.
Do you require labs before prescribing?
Yes. The Biomarker Audit is drawn before any first prescription and repeats every 90 days. It covers ApoB, Lp(a), hs-CRP, HbA1c, fasting insulin, a full lipid panel, a comprehensive metabolic panel, a CBC and TSH with reflex to free T4.
Do you prescribe compounded GLP-1 medication?
Never. We prescribe branded, FDA-approved medication only. Compounded GLP-1 is a different product with a different risk profile and we will not prescribe it.
One last thing
The maintenance dose is the number that exposes the industry's incentive problem more cleanly than any other. Ask every program you evaluate the same question. Who earns more when my dose goes up? A practice with a clean answer has usually cleaned up everything else, because the titration is where the conflict lives and everything else follows from it.
Related Guides
- Medical weight loss
- What a Biomarker Audit includes
- Cardiometabolic Optimization: the definitive guide
- The GLP-1 pricing guide: Wegovy, Zepbound, Ozempic
References
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1), New England Journal of Medicine, 2021. doi.org/10.1056/NEJMoa2032183
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1), New England Journal of Medicine, 2022. doi.org/10.1056/NEJMoa2107519
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4), JAMA, 2024. PubMed
- FDA, medications containing semaglutide marketed for type 2 diabetes or weight loss. fda.gov